Closing the Revolving Door at HHS

The Food and Drug Administration plans to ban employees of regulated companies, including drug manufacturers, from serving on the agency’s advisory committees. The new policy is aimed at combating industry influence and conflicts of interest, but will it make a difference? We are joined by Genevieve Kanter, an Associate Professor at the USC Price School, who has researched conflicts of interest at the FDA as well as the “revolving door” of people moving between jobs in government and regulated industries.